NO961887L - -adrenergiske agonister - Google Patents

-adrenergiske agonister

Info

Publication number: NO961887L
Authority: NO; Norway
Prior art keywords: adrenergic agonists; adrenergic; agonists
Prior art date: 1995-05-10

Application number

NO961887A

Other languages

English (en)

Other versions

NO961887D0 (no

NO307049B1 (no

Inventor

Robert Lee Dow

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-05-10

Filing date

1996-05-09

Publication date

1996-11-11

1996-05-09 Application filed by Pfizer filed Critical Pfizer

1996-05-09 Publication of NO961887D0 publication Critical patent/NO961887D0/no

1996-11-11 Publication of NO961887L publication Critical patent/NO961887L/no

2000-01-31 Publication of NO307049B1 publication Critical patent/NO307049B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Child & Adolescent Psychology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Fodder In General (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO961887A 1995-05-10 1996-05-09 Forbindelse som er <Beta>-adrenergiske agonister, anvendelse derav og farmasøytisk blanding NO307049B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/IB1995/000344 WO1996035671A1 (en)	1995-05-10	1995-05-10	β-ADRENERGIC AGONISTS
CA002220399A CA2220399A1 (en)	1995-05-10	1995-05-10	.beta.-adrenergic agonists
HU9601240A HUP9601240A1 (en)	1995-05-10	1996-05-09	Pyridin and pyrimidin derivatives, suitable as beta-adrenerg agonists, pharmaceutical compositions containing the same and their intermediates

Publications (3)

Publication Number	Publication Date
NO961887D0 NO961887D0 (no)	1996-05-09
NO961887L true NO961887L (no)	1996-11-11
NO307049B1 NO307049B1 (no)	2000-01-31

Family

ID=89993954

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO961887A NO307049B1 (no)	1995-05-10	1996-05-09	Forbindelse som er <Beta>-adrenergiske agonister, anvendelse derav og farmasøytisk blanding

Country Status (19)

Country	Link
US (1)	US5977124A (no)
EP (1)	EP0824519A1 (no)
JP (1)	JPH11504649A (no)
KR (1)	KR100190259B1 (no)
AU (1)	AU706235B2 (no)
BR (1)	BR9602209A (no)
CA (1)	CA2220399A1 (no)
CO (1)	CO4440567A1 (no)
CZ (1)	CZ132196A3 (no)
FI (1)	FI974172L (no)
HU (1)	HUP9601240A1 (no)
IL (1)	IL118115A0 (no)
MX (1)	MX9708621A (no)
NO (1)	NO307049B1 (no)
NZ (1)	NZ286548A (no)
PL (1)	PL314120A1 (no)
SG (1)	SG43365A1 (no)
TR (1)	TR199600358A2 (no)
WO (1)	WO1996035671A1 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5981562A (en) *	1996-01-30	1999-11-09	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US6008361A (en) *	1996-04-09	1999-12-28	Pfizer Inc.	Substituted pyridines
US6031105A (en) *	1996-04-09	2000-02-29	Pfizer Inc	Substituted pyridines
KR20000053314A (ko)	1996-11-14	2000-08-25	디. 제이. 우드, 스피겔 알렌 제이	치환된 피리딘의 제조 방법
US6001856A (en) *	1997-06-13	1999-12-14	Pfizer Inc.	β-adrenergic agonists to reduce a wasting condition
EP0920864A1 (en) *	1997-12-03	1999-06-09	Pfizer Products Inc.	Combination therapy including a specific beta-3 agonist and an anorectic agent
US6657063B1 (en) *	1998-04-30	2003-12-02	Pfizer Inc.	Combinations of β3 agonists and growth hormone secretagogues
US6090942A (en) *	1998-10-15	2000-07-18	Pfizer Inc.	Process and intermediates for a β3 -adrenergic receptor agonist
ATE280167T1 (de)	1999-07-23	2004-11-15	Pfizer Prod Inc	Zwischenprodukte und ein verfahren zur herstellung von beta3-adrenergischer rezeptor- agoniste
AU7315700A (en)	1999-09-20	2001-04-24	Takeda Chemical Industries Ltd.	Melanin concentrating hormone antagonist
US6451587B1 (en)	1999-09-29	2002-09-17	Pfizer Inc.	Microbial asymmetric reduction of 2-chloro-1-[-6-(2,5-dimethyl-pyrrol-1-yl)-pyridin-3-yl]-ethanone
WO2001083451A1 (en) *	2000-04-28	2001-11-08	Asahi Kasei Kabushiki Kaisha	Novel bicyclic compounds
EE200300191A (et) *	2000-10-20	2003-10-15	Pfizer Products Inc.	Alfa-arüül-etanoolamiinid ja nende kasutamine beeta-3 adrenergiliste retseptorite agonistidena
EP1236723A1 (en) *	2001-03-01	2002-09-04	Pfizer Products Inc.	Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
DOP2003000587A (es) *	2002-02-27	2003-08-30	Pfizer Prod Inc	AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
US6864268B2 (en)	2002-02-27	2005-03-08	Pfizer Inc.	β3 adrenergic receptor agonists
AU2003209527A1 (en)	2002-02-27	2003-09-09	Pfizer Products Inc.	Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
BR0307996A (pt) *	2002-02-27	2004-12-07	Pfizer Prod Inc	Processos e intermediários úteis na preparação de receptores de agonistas beta3-adrenérgicos
US20050075323A1 (en) *	2003-03-05	2005-04-07	Pfizer Inc	Beta3 adrenergic receptor agonists and uses thereof
EP1477167A1 (en) *	2003-05-15	2004-11-17	Pfizer Limited	[(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
US7375100B2 (en) *	2003-06-04	2008-05-20	Pfizer Inc	2-amino-pyridine derivatives useful for the treatment of diseases
GB0312832D0 (en) *	2003-06-04	2003-07-09	Pfizer Ltd	2-amino-pyridine derivatives useful for the treatment of diseases
KR101071748B1 (ko) *	2003-12-23	2011-10-11	아스텔라스세이야쿠 가부시키가이샤	아미노알콜 유도체
WO2006051373A1 (en) *	2004-11-12	2006-05-18	Pfizer Limited	Compounds for the treatment of diseases
WO2006133160A2 (en)	2005-06-06	2006-12-14	Georgetown University	Compositions and methods for lipo modeling
BRPI0903206E2 (pt)	2009-09-01	2015-07-28	Da Silva Antonio Carlos Nunes Ett	Unidade processadora e método de processamento de fraldas e absorventes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4358455A (en) *	1980-12-23	1982-11-09	Merck & Co., Inc.	Aralkylamindethanol heterocyclic compounds
EP0105053B1 (en) *	1982-10-01	1988-01-20	Merck & Co. Inc.	Aralkylaminoethanol heterocyclic compounds
CA1287061C (en) *	1986-06-27	1991-07-30	Roche Holding Ltd.	Pyridine ethanolamine derivatives
GB8703007D0 (en) *	1987-02-10	1987-03-18	Glaxo Group Ltd	Chemical compounds
US5019578A (en) *	1987-11-27	1991-05-28	Merck & Co., Inc.	β-adrenergic agonists
NZ226991A (en) *	1987-11-27	1992-03-26	Merck & Co Inc	Alpha-heterocyclically-substituted ethanolamines and use as animal growth promotors
US5216170A (en) *	1989-01-26	1993-06-01	Bayer Aktiengesellschaft	(2-aminopropyl) pyridines useful as intermediates
GB9209076D0 (en) *	1992-04-27	1992-06-10	Ici Plc	Chemical compounds
JPH08502278A (ja) *	1992-10-16	1996-03-12	ビイクネダーラントベスローテンフェンノートシャップ	置換されたエタノールアミンエステル
US5726192A (en) *	1992-12-29	1998-03-10	Smithkline Beecham Corporation	Platelet aggregation inhibiting compounds
US5451677A (en) *	1993-02-09	1995-09-19	Merck & Co., Inc.	Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
WO1994025427A1 (en) *	1993-04-26	1994-11-10	Fujisawa Pharmaceutical Co., Ltd.	Ethanolamine derivatives useful for the treatment of gastrointestinal disorders
WO1994029290A1 (en) *	1993-06-14	1994-12-22	Pfizer Inc.	Secondary amines as antidiabetic and antiobesity agents
JPH08165276A (ja) *	1994-12-14	1996-06-25	Dainippon Pharmaceut Co Ltd	２−アルキルアミノ−１−フェニルエタノール誘導体

1995
- 1995-05-10 US US08/945,551 patent/US5977124A/en not_active Expired - Fee Related
- 1995-05-10 EP EP95915995A patent/EP0824519A1/en not_active Ceased
- 1995-05-10 MX MX9708621A patent/MX9708621A/es not_active Application Discontinuation
- 1995-05-10 FI FI974172A patent/FI974172L/fi unknown
- 1995-05-10 WO PCT/IB1995/000344 patent/WO1996035671A1/en not_active Ceased
- 1995-05-10 JP JP8533903A patent/JPH11504649A/ja active Pending
- 1995-05-10 CA CA002220399A patent/CA2220399A1/en not_active Abandoned
1996
- 1996-05-02 IL IL11811596A patent/IL118115A0/xx unknown
- 1996-05-03 TR TR96/00358A patent/TR199600358A2/xx unknown
- 1996-05-07 CZ CZ961321A patent/CZ132196A3/cs unknown
- 1996-05-07 SG SG1996009751A patent/SG43365A1/en unknown
- 1996-05-08 CO CO96022964A patent/CO4440567A1/es unknown
- 1996-05-08 PL PL96314120A patent/PL314120A1/xx unknown
- 1996-05-09 AU AU52185/96A patent/AU706235B2/en not_active Ceased
- 1996-05-09 NZ NZ286548A patent/NZ286548A/en unknown
- 1996-05-09 KR KR1019960015262A patent/KR100190259B1/ko not_active Expired - Fee Related
- 1996-05-09 HU HU9601240A patent/HUP9601240A1/hu unknown
- 1996-05-09 NO NO961887A patent/NO307049B1/no not_active IP Right Cessation
- 1996-05-10 BR BR9602209A patent/BR9602209A/pt active Search and Examination

Also Published As

Publication number	Publication date
HU9601240D0 (en)	1996-07-29
FI974172A7 (fi)	1997-11-07
CA2220399A1 (en)	1996-11-14
KR100190259B1 (ko)	1999-06-01
TR199600358A2 (tr)	1996-11-21
NO961887D0 (no)	1996-05-09
CZ132196A3 (en)	1997-03-12
MX9708621A (es)	1998-02-28
FI974172A0 (fi)	1997-11-07
AU706235B2 (en)	1999-06-10
FI974172L (fi)	1997-11-07
HUP9601240A1 (en)	1997-09-29
SG43365A1 (en)	1997-10-17
IL118115A0 (en)	1996-09-12
US5977124A (en)	1999-11-02
JPH11504649A (ja)	1999-04-27
KR960041168A (ko)	1996-12-19
AU5218596A (en)	1996-11-21
PL314120A1 (en)	1996-11-12
WO1996035671A1 (en)	1996-11-14
CO4440567A1 (es)	1997-05-07
NO307049B1 (no)	2000-01-31
EP0824519A1 (en)	1998-02-25
BR9602209A (pt)	1998-04-07
NZ286548A (en)	1998-03-25

Publication	Publication Date	Title
EP0858444A4 (en)	1999-12-01	Cyclopentyl tachykinin receptor antagonists
DE69635315D1 (de)	2005-11-24	Kodeverteilvielfachzugriffskommunikationssystem
DE69629037T2 (de)	2004-01-15	Oberflächenplasmanenresonanzmassenspektrometrie
DE69625472D1 (de)	2003-01-30	Schraubrohrverbindung
NO961887D0 (no)	1996-05-09	-adrenergiske agonister
DE59609887D1 (de)	2003-01-02	Substituierte cyanophenyluracile
DE69626325D1 (de)	2003-03-27	Einlegesohle
DE69633171D1 (de)	2004-09-23	Mutierte luziferasen
DE69624969D1 (de)	2003-01-09	Fahrzeugodometerkorrektursystem
DE69623501D1 (de)	2002-10-10	Tiernährungssauger
DE69617145D1 (de)	2002-01-03	Umlenkbeschlagstruktur
NO962039D0 (no)	1996-05-20	Personsökesystem
FI974170L (fi)	1997-11-07	B-adrenergisiä agonisteja
DE69632434D1 (de)	2004-06-17	Strangiessenanlage
DE59610332D1 (de)	2003-05-15	Substituierte aminouracile
DE69623189D1 (de)	2002-10-02	Chipkartenabtaster
DE69633323D1 (de)	2004-10-14	Pyrazolylazophenolfarbstoff
BR9609319A (pt)	1999-07-06	Carbonilaminofeniluracilas substituídas
BR9608890A (pt)	1999-06-15	N-metilenotiouréias substituídas
DE69631825D1 (de)	2004-04-15	Kurbelwellenfräsgerät
DE69624031D1 (de)	2002-11-07	Spiralverdrängermaschine
DE69629479D1 (de)	2003-09-18	Bremsbacke
DE69631954D1 (de)	2004-04-29	Spreizspektrumnachrichtenübertragungssystem
DE69630477D1 (de)	2003-12-04	Breitbandsignalkodierer
BR9603376A (pt)	1998-05-12	Tetrahidro-5-nitro-pirimidinas substituídas

Legal Events

Date	Code	Title	Description
2002-01-02	MM1K	Lapsed by not paying the annual fees	Free format text: LAPSED IN NOVEMBER 2001